Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics

Journal of Neuroimmunology

Volumn 277, Issue 1-2, 2014, Pages 145-152

  Berger, Thomas ^a   Jacobi, Christian ^b   Haas, Judith ^c   Ransmayr, Gerhard ^d   Guger, Michael ^d   Zettl, Uwe K ^e   Di Pauli, Franziska ^a   Taumberger, Birgit ^f   Wietek, Stefan ^f   Meuer, Stefan ^g   Reindl, Markus ^a   Giese, Thomas ^g  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b KRANKENHAUS NORDWEST   (Germany)

^c Jewish Hospital Berlin   (Germany)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f Octapharma Pharmazeutika Produktions GmbH   (Austria)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Individualized immunotherapy; Intravenous immunoglobulin (IVIG); Prospective clinical study; Prospective responder discrimination; Relapsing remitting multiple sclerosis (RRMS)

Indexed keywords

IMMUNOGLOBULIN G; CYTOKINE; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; MESSENGER RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; EX VIVO STUDY; EXPLORATORY RESEARCH; FEMALE; FUNCTIONAL GENOMICS; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VIVO STUDY; MALE; MULTIPLE SCLEROSIS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PREDICTION; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CLINICAL TRIAL; DISABILITY; FLOW CYTOMETRY; GENETICS; METABOLISM; MULTICENTER STUDY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; PHARMACOGENETICS; REPRODUCIBILITY;

CYTOKINES; DISABILITY EVALUATION; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER;

EID: 84919330785     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.10.001     Document Type: Article

References (21)

1. Hafler D.A., et al. Multiple sclerosis. Immunol. Rev. 2005, 204:208-231.
2. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
3. Lucchinetti C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47(6):707-717.
4. Bruck W., Stadelmann C. The spectrum of multiple sclerosis: new lessons from pathology. Curr. Opin. Neurol. 2005, 18(3):221-224.
5. Rothfelder U., Neu I., Pelka R. Therapy of multiple sclerosis with immunoglobulin G. MMW Munch. Med. Wochenschr. 1982, 124(4):74-78.
6. Winkelmann A., Zettl U.K. Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous system. Curr. Pharm. Des. 2012, 18(29):4570-4582.
7. Fazekas F., et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997, 349(9052):589-593.
8. Achiron A., et al. Intravenous immunoglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis-the Israeli experience. MS Study Group. Mult. Scler. 1997, 3(2):142-144.
9. Sorensen P.S., et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998, 50(5):1273-1281.
10. Noseworthy J.H., et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000, 55(8):1135-1143.
11. Goodin D.S., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58(2):169-178.
12. Fergusson D., et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005, 45(10):1640-1657.
13. Fazekas F., et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008, 71(4):265-271.
14. Elovaara I., et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol. 2008, 15(9):893-908.
15. Boros P., Gondolesi G., Bromberg J.S. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl. 2005, 11(12):1469-1480.
16. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 2001, 345(10):747-755.
17. Siberil S., et al. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann. N. Y. Acad. Sci. 2007, 1110:497-506.
18. Nimmerjahn F. Activating and inhibitory FcgammaRs in autoimmune disorders. Springer Semin. Immunopathol. 2006, 28(4):305-319.
19. Jacobi C., et al. Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity. Clin. Immunol. 2009, 133(3):393-401.
20. McDonald W.I., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50(1):121-127.
21. Polman C.H., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58(6):840-846.